{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=31",
    "query": {
      "condition": "Phase 1",
      "page": 31
    },
    "page_size": 10
  },
  "pagination": {
    "page": 31,
    "page_size": 10,
    "total_count": 18603,
    "total_pages": 1861,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=32&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=30&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T19:45:21.108Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03279120",
      "title": "Safety, PK, and PD Study of IVRs Releasing TFV and LNG",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anti-Infective Agents",
        "Anti-Retroviral Agents",
        "Contraceptive Usage"
      ],
      "interventions": [
        {
          "name": "TFV/LNG IVR",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CONRAD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 66,
      "start_date": "2017-09-28",
      "completion_date": "2018-12-26",
      "has_results": false,
      "last_update_posted_date": "2019-07-23",
      "last_synced_at": "2026-10-25T19:45:21.108Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03279120"
    },
    {
      "nct_id": "NCT00988624",
      "title": "A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Huntington Disease"
      ],
      "interventions": [
        {
          "name": "Dimebon IR Tablet",
          "type": "DRUG"
        },
        {
          "name": "Dimebon MR1",
          "type": "DRUG"
        },
        {
          "name": "Dimebon MR2",
          "type": "DRUG"
        },
        {
          "name": "Dimebon MR3",
          "type": "DRUG"
        },
        {
          "name": "Dimebon MR4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2009-10",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2010-01-12",
      "last_synced_at": "2026-10-25T19:45:21.108Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00988624"
    },
    {
      "nct_id": "NCT03767582",
      "title": "Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)",
        "Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Stereotactic Body Radiation (SBRT)",
          "type": "RADIATION"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "CCR2/CCR5 dual antagonist",
          "type": "DRUG"
        },
        {
          "name": "GVAX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2019-12-12",
      "completion_date": "2025-02-01",
      "has_results": true,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-10-25T19:45:21.108Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03767582"
    },
    {
      "nct_id": "NCT06204679",
      "title": "Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer Study"
      ],
      "interventions": [
        {
          "name": "Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions",
          "type": "DRUG"
        },
        {
          "name": "Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions",
          "type": "DRUG"
        },
        {
          "name": "Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Atea Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 42,
      "start_date": "2023-12-14",
      "completion_date": "2024-08-25",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-25T19:45:21.108Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06204679"
    },
    {
      "nct_id": "NCT00452673",
      "title": "Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 52,
      "start_date": "2007-06",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2015-03-24",
      "last_synced_at": "2026-10-25T19:45:21.108Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Chicago, Illinois • New York, New York + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00452673"
    },
    {
      "nct_id": "NCT00743769",
      "title": "A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myocardial Infarction",
        "Myocardial Ischemia"
      ],
      "interventions": [
        {
          "name": "thymosin beta 4",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "RegeneRx Biopharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 0,
      "start_date": "2008-04",
      "completion_date": "2017-01-01",
      "has_results": false,
      "last_update_posted_date": "2017-04-17",
      "last_synced_at": "2026-10-25T19:45:21.108Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00743769"
    },
    {
      "nct_id": "NCT00893360",
      "title": "CArdiosphere-Derived aUtologous Stem CElls to Reverse ventricUlar dySfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recent Myocardial Infarction",
        "Ventricular Dysfunction"
      ],
      "interventions": [
        {
          "name": "Autologous stem cell infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 31,
      "start_date": "2009-05",
      "completion_date": "2012-02",
      "has_results": false,
      "last_update_posted_date": "2014-02-12",
      "last_synced_at": "2026-10-25T19:45:21.108Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Baltimore, Maryland",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00893360"
    },
    {
      "nct_id": "NCT06541262",
      "title": "Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma",
        "Ewing Sarcoma",
        "Osteosarcoma",
        "Rhabdomyosarcoma",
        "Liposarcoma"
      ],
      "interventions": [
        {
          "name": "Silmitasertib",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 104,
      "start_date": "2024-10-30",
      "completion_date": "2035-11-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-25T19:45:21.108Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Oakland, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06541262"
    },
    {
      "nct_id": "NCT04640246",
      "title": "Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Tumor, Solid",
        "Refractory Cancer"
      ],
      "interventions": [
        {
          "name": "TBX-3400",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Taiga Biotechnologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2021-01-25",
      "completion_date": "2023-04",
      "has_results": false,
      "last_update_posted_date": "2022-02-02",
      "last_synced_at": "2026-10-25T19:45:21.108Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04640246"
    },
    {
      "nct_id": "NCT07567846",
      "title": "A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Prostate Cancer",
        "Metastatic Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "GDC-1261",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 260,
      "start_date": "2026-04-29",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-25T19:45:21.108Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Nashville, Tennessee",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07567846"
    }
  ]
}